Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine

First published 25/06/2021

Last updated 24/01/2025

EU PAS number:

EUPAS41623

Study

Ongoing

Documents

Study protocol

Initial protocol

C4591021_PROTOCOL_20MAY2021____

English (844.83 KB - PDF)View document

Updated protocol

C4591021_PROTOCOL AMENDMENT 5_V7.0_15MAY2024.pdf

First published: 18/06/2024

English (1.22 MB - PDF)View document

Study results

Study report

C4591021_PROGRESS REPORT_27SEP2021

English (1.82 MB - PDF)View document

C4591021 NI Study Report Abstract - interim 1.pdf

English (1.29 MB - PDF)View document

c4591021-interim2-abstract.pdf

English (1.84 MB - PDF)View document

c4591021-interim3-abstract.pdf

English (659.37 KB - PDF)View document

c4591021-interim-abstract.pdf

English (703.59 KB - PDF)View document

C4591021 Interim 5 Study Report Abstract .pdf

English (120.38 KB - PDF)View document

Other information

Study, other information

C4591021_PROTOCOL AMENDMENT 2_31MAR2022

English (4.11 MB - PDF)View document

Secondary tabs